|
|
|
|
|||||
|
|
|
Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to invest in now. On July 8, Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx SE (NASDAQ:ARGX) to Buy from Hold with a EUR 550 price target.
Argenx SE (NASDAQ:ARGX) reported that it generated global product net sales of $790 million in Q1 2025, inclusive of both VYVGART and VYVGART SC.
The company also exhibited strong underlying fundamentals across key patient and prescriber metrics, with 99% product net sales growth year-over-year compared to Q1 2024, along with a 7% product net sales growth from Q4 2024.
Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 3 hours | |
| Jul-28 | |
| Jul-24 | |
| Jul-21 | |
| Jul-03 | |
| Jun-30 | |
| Jun-30 | |
| Jun-24 | |
| Jun-20 | |
| Jun-17 | |
| Jun-10 | |
| Jun-06 | |
| Jun-06 | |
| Jun-03 | |
| Jun-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite